Revolution Medicines, Inc.
RVMD · XNASCIK 1628171fmd_0N4KAXK9FQ40ATKA91P1B00E26Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 32 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 20 | 50 | 43 | 29 | 35 | 12 | 0 | 0 |
| Research and development | 51 | 92 | 132 | 187 | 253 | 423 | 592 | 987 |
| Total operating expenses | 60 | 104 | 154 | 217 | 294 | 499 | 690 | 1,182 |
| Operating income | (40) | (54) | (111) | (188) | (258) | (487) | (690) | (1,182) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 |
| Interest and investment income | 1 | 2 | 2 | 1 | 9 | 47 | 87 | 91 |
| Other non-operating income (expense) | (1) | 2 | 2 | 1 | 9 | 47 | 89 | 51 |
| Income before taxes | (42) | (52) | (109) | (187) | (249) | (440) | (601) | (1,131) |
| Income tax expense | – | (4) | (0) | 0 | (0) | (4) | (1) | 0 |
| Net income from continuing operations | – | (48) | (108) | (187) | (249) | (436) | (600) | (1,131) |
| Net income | (42) | (48) | (108) | (187) | (249) | (436) | (600) | (1,131) |
| Net income to common shareholders | (49) | (62) | (110) | (187) | (249) | (436) | (600) | (1,131) |